---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044203"
form_type: "8-K/A"
ticker: "PLSH"
cik: "0001552189"
company_name: "PANACEA LIFE SCIENCES HOLDINGS, INC."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:35:10.504847+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern

## Summary
- N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.
- Auditors express substantial doubt about N7's ability to continue as a going concern.
- Acquisition consideration: 784 preferred shares convertible into 7.84M common shares of Panacea.
- N7 started operations Nov 2022; negative cash flows and accumulated deficit noted.
- Pro forma financials combine Panacea and N7 for six months ended June 30, 2023 and year ended Dec 31, 2022.

## SEC filing metadata
- accession: 0001493152-23-044203
- form_type: 8-K/A
- ticker: PLSH
- cik: 0001552189
- company_name: PANACEA LIFE SCIENCES HOLDINGS, INC.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/0001493152-23-044203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552189/000149315223044203/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044203
- JSON: https://secwatch.observer/filing/0001493152-23-044203.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.